At Photonic Pharma LLC, we focus on the early phase of drug development - Lead Discovery - using a game-changing technology platform that combines breakthroughs in fluorescence biosensor engineering and fluorescence lifetime detection in living cells. Thus we achieve a dramatic 30-fold increase in the precision of high-throughput screening of small-molecule libraries, with the potential to transform the productivity of pharmaceutical development.
We partner with industrial and academic collaborators, applying our proprietary advancements in structure-based drug-screening technology, to discover novel small-molecule effectors of therapeutically important protein targets. We have assembled a robust and highly integrated network of techniques, concepts, facilities and collaborators to address a wide range of therapeutic goals.
April 28, 2017
Photonic Pharma is a finalist presenting at the Walleye Tank Life Sciences Pitch Competition.
April 18, 2017
Photonic Pharma presented as one of the 40 "Best University Startups 2017" at the NCET2 University Startups Conference and Demo Day in Washington D.C.
March 28, 2017
Photonic Pharma's co-founders were recognized at the Inventor Recognition Event held by the Office for Technology Commercialization at the University of Minnesota.
For more information, visit the Photonic Pharma News tab.